Why the study?
Data regarding the relationship between LDL-C levels and bleeding events in patients with AF remained unaddressed.
Does LDL-C < 70 mg/dl increase the risk of in-hospital bleeding in patients with atrial fibrillation?
Does LDL-C < 70 mg/dl increase the risk of in-hospital bleeding in patients with atrial fibrillation?
In patients with atrial fibrillation, lower LDL-C levels (<70 mg/dl) at admission are associated with a significantly increased risk of in-hospital bleeding events.
LDL-C–bleeding link in AF is hypothesis-generating; leaves open whether LDL-C modification alters risk.
Background and aims Emerging evidence indicates a relationship between low-density lipoprotein cholesterol (LDL-C) levels and bleeding. However, data regarding the relationship between LDL-C levels and bleeding events in patients with atrial fibrillation (AF) remain unfilled. This study is aimed to examine the relationship between LDL-C levels and the risk of in-hospital bleeding in patients with AF. Methods and results In this multi-centered observational study, 25,380 patients with AF were enrolled; 14,071 (55.4%) and 11 309 (44.6%) were men and women, respectively, and the mean age was 69.51 ± 11.88 years. After adjusting for covariates, with LDL-C ≥ 70 mg/dl as the reference, LDL-C < 70 mg/dl was associated with a higher risk of any bleeding event [adjusted odds ratio [aOR]: 1.63, 95% confidence interval [CI]: 1.12–2.35; P = 0.009], major bleeding events (aOR: 1.48, 95% CI: 0.99–2.20; P = 0.05), and gastrointestinal bleeding events (aOR: 2.11, 95% CI: 1.27–3.50; P = 0.004) in the multivariate logistic regression model. The restricted cubic spline model showed an L-shaped relationship for bleeding events, with a higher risk at lower LDL-C levels. The nonlinear relationship between LDL-C levels and the risk of bleeding persisted among the subgroups. Conclusions This nationwide and multi-centered AF registry study found an L-shaped relationship between LDL-C levels at admission and in-hospital bleeding events, with a greater risk at lower LDL-C levels. Further studies are needed to establish LDL-C as a factor for risk stratification and management of bleeding events in patients with AF. Clinical Trial Registration [ http://www.clinicaltrials.gov ], identifier [NCT02309398].
No takes yet. Share an insight, caveat, or question.
Lin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: